Other Events ·
On September 2, 2026, Summit Therapeutics announced that partner Akeso reported positive overall survival results from…
SMMTSummit Therapeutics Inc.
On September 2, 2026, Summit Therapeutics announced that partner Akeso reported positive overall survival results from the Phase III HARMONi-2 study of ivonescimab in PD-L1-positive non-small cell lung cancer. Ivonescimab demonstrated a statistically significant improvement compared to pembrolizumab monotherapy, reinforcing its approval by China’s NMPA in April 2025. Summit continues global development with the HARMONi BLA for FDA acceptance and a PDUFA date of November 14, 2026. The company operates as a biopharmaceutical oncology firm focused on discovering and developing medicinal therapies.